CLL Advocates Pharmac Submission

CLL Advocates NZ has made a formal submission to Pharmac supporting the proposal to fund two time‑limited treatment combinations for first‑line CLL care: Venetoclax with Ibrutinib, and Venetoclax with Obinutuzumab.

This represents an important step toward giving New Zealanders access to modern, internationally recognised therapies. Our submission welcomes the proposal, outlines several refinements to ensure equitable access for patients who have been self‑funding treatment, and highlights the need for flexibility where side‑effects or clinical circumstances require alternative options.

Here is a link to the submission: CLL Pharmac Submission

Here a link to the flowchart for the Proposed Funded CLL Treatment Pathway: Treatment Pathways